Trial Profile

A Phase II trial of ReJoin (autologous Human Adipose-derived Mesenchymal Progenitor Cell) for knee osteoarthritis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 22 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous adipose-derived mesenchymal stem cell therapy-AbelZeta Pharma (Primary)
Indications Osteoarthritis
Focus Adverse reactions; Therapeutic Use

20 Nov 2023 According to a Cellular Biomedicine Group media release, the Cellular Biomedicine Group has changed its name to has changed its name to AbelZeta Pharma, Inc. (AbelZeta), after spin-off of the Company's stem cell business division. AbelZeta to focus greater resources on the development of immune cell therapy for cancer and Inflammation & Immunology (I&I) diseases.
27 Sep 2019 According to the Cellular Biomedicine Group media release, the company announced that the ReJoin therapy for Knee Osteoarthritis(KOA) received stem cell drug application acceptance for a phase II clinical trial by China NMPA.
18 Sep 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com